NZ609594A - Eph receptor expression in tumor stem cells - Google Patents

Eph receptor expression in tumor stem cells

Info

Publication number
NZ609594A
NZ609594A NZ609594A NZ60959411A NZ609594A NZ 609594 A NZ609594 A NZ 609594A NZ 609594 A NZ609594 A NZ 609594A NZ 60959411 A NZ60959411 A NZ 60959411A NZ 609594 A NZ609594 A NZ 609594A
Authority
NZ
New Zealand
Prior art keywords
stem cells
receptor expression
tumor stem
eph receptor
eph
Prior art date
Application number
NZ609594A
Other languages
English (en)
Inventor
Angelo Luigi Vescovi
Elena Binda
Original Assignee
Stemgen S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S P A filed Critical Stemgen S P A
Publication of NZ609594A publication Critical patent/NZ609594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ609594A 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells NZ609594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
PCT/EP2011/067114 WO2012042021A1 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Publications (1)

Publication Number Publication Date
NZ609594A true NZ609594A (en) 2015-01-30

Family

ID=43856109

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ609594A NZ609594A (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Country Status (11)

Country Link
US (1) US9078857B2 (enExample)
EP (2) EP2446895A1 (enExample)
JP (4) JP2013540117A (enExample)
KR (2) KR20130095286A (enExample)
AU (1) AU2011310109B2 (enExample)
CA (1) CA2813101C (enExample)
DK (1) DK2621513T3 (enExample)
ES (1) ES2616444T3 (enExample)
NZ (1) NZ609594A (enExample)
PL (1) PL2621513T3 (enExample)
WO (1) WO2012042021A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
RU2016119491A (ru) 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
SMT202100146T1 (it) 2014-04-30 2021-05-07 Pfizer Coniugati di anticorpo anti-ptk7-farmaco
ES2796973T3 (es) 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
US10783439B2 (en) * 2015-05-08 2020-09-22 FlowJo, LLC Plugin interface and framework for integrating a remote server with sample data analysis software
WO2017081686A1 (en) 2015-11-10 2017-05-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US20240226175A1 (en) * 2020-03-31 2024-07-11 Keio University Therapeutic agent using genome-edited pluripotent stem cell
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060130038A (ko) * 2003-10-15 2006-12-18 메디뮨 인코포레이티드 리스테리아에 의거한 ＥｐｈＡ２ 백신
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
WO2009028639A1 (ja) * 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体

Also Published As

Publication number Publication date
AU2011310109A1 (en) 2013-05-02
DK2621513T3 (en) 2017-03-06
JP2018048151A (ja) 2018-03-29
WO2012042021A1 (en) 2012-04-05
EP2621513B1 (en) 2016-12-28
JP6523910B2 (ja) 2019-06-05
CA2813101C (en) 2018-10-30
US9078857B2 (en) 2015-07-14
JP2020037579A (ja) 2020-03-12
JP6618968B2 (ja) 2019-12-11
KR20130095286A (ko) 2013-08-27
KR101719966B1 (ko) 2017-03-24
JP2016094391A (ja) 2016-05-26
PL2621513T3 (pl) 2017-06-30
AU2011310109B2 (en) 2014-11-20
JP2013540117A (ja) 2013-10-31
US20120083454A1 (en) 2012-04-05
ES2616444T3 (es) 2017-06-13
KR20160027106A (ko) 2016-03-09
EP2621513A1 (en) 2013-08-07
CA2813101A1 (en) 2012-04-05
EP2446895A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
AU2018256508A1 (en) Individualized vaccines for cancer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX2011007930A (es) Conjugados de insulina cristalina.
NZ584458A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
NZ609967A (en) Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12012501782A1 (en) Phytocannabinoids in the treatment of cancer
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
GB201309758D0 (en) Generation of neural stem cells from human trophoblast stem cells
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2013006595A (es) Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
MX2012008958A (es) Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
SA515360414B1 (ar) صلب من النوعية ذات درجة الحرارة العالية لمعدات مفاعل ذي طبقة سفلية مائعة
WO2013016452A3 (en) Cancer treatment using bmp inhibitor
NZ588435A (en) Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
CA145614S (en) Cushion for a patient interface assembly
MX365464B (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
NZ595440A (en) Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
MX2015006004A (es) Inhibicion de celulas cancerosas resistentes a farmacos.
WO2008134752A3 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2016 BY CPA GLOBAL

Effective date: 20150815

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2017 BY CPA GLOBAL

Effective date: 20160819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2018 BY CPA GLOBAL

Effective date: 20170817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2019 BY CPA GLOBAL

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2020 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20190927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2022 BY DENNEMEYER + CO.

Effective date: 20210921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2023 BY DENNEMEYER + CO.

Effective date: 20220929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2024 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20230918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2025 BY DENNEMEYER ET CO

Effective date: 20240927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2026 BY DENNEMEYER + CO. SARL

Effective date: 20251006